---
figid: PMC4896389__emss-68131-f004
figlink: /pmc/articles/PMC4896389/figure/F4/
number: Figure 4
caption: After radiotherapy, there are numerous potential targets within the tumour
  microenvironment (TME) whose modulation may lead to radiosensitisation. These are
  categorised broadly by area of biological effect — a) hypoxia, b) fibrosis and CAF
  related, and c) immune — and their actions portrayed in relation to the effects
  of radiotherapy on the TME summarised in . Ongoing clinical trials addressing these
  in combination with radiotherapy are addressed in the .a) Hypoxia targets can be
  further subdivided into those that affect endothelial cell survival (for example,
  targeting integrins), that normalise vasculature (for example, antagonising VEGF),
  that prevent vasculogenesis (for example, targeting CXCL12 recruitment of endothelial
  progenitor cells), that alter oxygen delivery (for example, ARCON therapy–), or
  that alter HIF-1α signalling (for example, the HIF-1α inhibitor YC-1).b) Fibrosis
  targets can be sub-categorised into those that affect stromal activation (for example,
  by inhibition of growth factors by suramin), that affect ECM remodelling (for example,
  targeting TN-C with the antibody 81C6, ), or that affect TGF-β signalling (for example,
  by targeting its receptor TGF-βR1 with the inhibitor SD-208).c) Immune targets can
  be divided into those that prime dendritic cells (for example, the TLR7 agonist
  imiquimod), that affect T-cell checkpoint co-stimulation (for example, the anti-CTLA-4
  antibody ipilumimab, , ), that affect T-cell exhaustion (for example, the anti-PD-1
  antibody Pembrolizumab) or that affect T-cell recruitment (for example, targeting
  the chemokine CXCL16). Oncoviruses are also an immunomodulatory stimulus and can
  be used to affect multiple aspects of the immune pathway in the irradiated TME (for
  example, GM-CSF-expressing herpes simplex virus, ).
pmcid: PMC4896389
papertitle: 'The Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance
  and Recurrence.'
reftext: Holly E. Barker, et al. Nat Rev Cancer. ;15(7):409-425.
pmc_ranked_result_index: '125957'
pathway_score: 0.8308321
filename: emss-68131-f004.jpg
figtitle: 'Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance and
  Recurrence'
year: ''
organisms: Homo sapiens
ndex: 2815ab24-df14-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4896389__emss-68131-f004.html
  '@type': Dataset
  description: After radiotherapy, there are numerous potential targets within the
    tumour microenvironment (TME) whose modulation may lead to radiosensitisation.
    These are categorised broadly by area of biological effect — a) hypoxia, b) fibrosis
    and CAF related, and c) immune — and their actions portrayed in relation to the
    effects of radiotherapy on the TME summarised in . Ongoing clinical trials addressing
    these in combination with radiotherapy are addressed in the .a) Hypoxia targets
    can be further subdivided into those that affect endothelial cell survival (for
    example, targeting integrins), that normalise vasculature (for example, antagonising
    VEGF), that prevent vasculogenesis (for example, targeting CXCL12 recruitment
    of endothelial progenitor cells), that alter oxygen delivery (for example, ARCON
    therapy–), or that alter HIF-1α signalling (for example, the HIF-1α inhibitor
    YC-1).b) Fibrosis targets can be sub-categorised into those that affect stromal
    activation (for example, by inhibition of growth factors by suramin), that affect
    ECM remodelling (for example, targeting TN-C with the antibody 81C6, ), or that
    affect TGF-β signalling (for example, by targeting its receptor TGF-βR1 with the
    inhibitor SD-208).c) Immune targets can be divided into those that prime dendritic
    cells (for example, the TLR7 agonist imiquimod), that affect T-cell checkpoint
    co-stimulation (for example, the anti-CTLA-4 antibody ipilumimab, , ), that affect
    T-cell exhaustion (for example, the anti-PD-1 antibody Pembrolizumab) or that
    affect T-cell recruitment (for example, targeting the chemokine CXCL16). Oncoviruses
    are also an immunomodulatory stimulus and can be used to affect multiple aspects
    of the immune pathway in the irradiated TME (for example, GM-CSF-expressing herpes
    simplex virus, ).
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CXCL14
  - CXCL9
  - CXCR4
  - PPBP
  - CXCL11
  - CXCL10
  - CXCL12
  - CXCL3
  - CXCL2
  - IL1B
  - IL1A
  - CXCL6
  - CSF2
  - CXCL5
  - ITPRIP
  - TRD
  - CTLA4
  - CD80
  - IL6
  - HIF1A
  - PDGFA
  - PDGFD
  - CXCL8
  - PF4
  - PIGF
  - TRG
  - FGF4
  - TRB
  - TRA
  - CXCL16
  - TGFBR1
  - TLR2
  - TLR3
  - TLR9
  - TLR8
  - HGF
  - EPAS1
  - ARNT2
  - HIF3A
  - ARNTL
  - ARNT
  - TLR5
  - TLR10
  - TNC
  - TNF
  - IL10
  - IL2
  - ASB1
  - CD28
  - CD8A
  - CD8B
  - CD86
  - CXCL13
  - CXCL1
  - FGF12
  - FGF11
  - PDGFC
  - PDGFB
  - CD274
  - FGF7
  - FGF6
  - FGF5
  - TLR6
  - FGF3
  - TGFB1
  - TGFB2
  - TGFB3
  - FGF1
  - FGF23
  - FGF19
  - VEGFC
  - VEGFD
  - PGF
  - VEGFA
  - TLR7
  - TLR1
  - TLR4
  - PDCD1
  - FGF13
  - FGF17
  - FGF16
  - FGF10
  - FGF9
  - FGF8
  - TNFRSF4
  - VEGFB
  - FGF2
  - KLRK1
  - FGF14
  - FGF22
  - FGF18
  - FGF21
  - FGF20
  - Cancer
genes:
- word: Chemokine
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL14
  entrez: '9547'
- word: CXCL9,
  symbol: CXCL9
  source: hgnc_symbol
  hgnc_symbol: CXCL9
  entrez: '4283'
- word: CXCR4
  symbol: CXCR4
  source: hgnc_symbol
  hgnc_symbol: CXCR4
  entrez: '7852'
- word: Chemokine
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: PPBP
  entrez: '5473'
- word: Chemokine
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL11
  entrez: '6373'
- word: CXCL10,
  symbol: CXCL10
  source: hgnc_symbol
  hgnc_symbol: CXCL10
  entrez: '3627'
- word: Chemokine
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL12
  entrez: '6387'
- word: Chemokine
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL3
  entrez: '2921'
- word: Chemokine
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL2
  entrez: '2920'
- word: IL-1
  symbol: IL1
  source: bioentities_symbol
  hgnc_symbol: IL1B
  entrez: '3553'
- word: IL-1
  symbol: IL1
  source: bioentities_symbol
  hgnc_symbol: IL1A
  entrez: '3552'
- word: Chemokine
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL6
  entrez: '6372'
- word: •GM-CSF
  symbol: GM-CSF
  source: hgnc_alias_symbol
  hgnc_symbol: CSF2
  entrez: '1437'
- word: GM-CSF
  symbol: GM-CSF
  source: hgnc_alias_symbol
  hgnc_symbol: CSF2
  entrez: '1437'
- word: Chemokine
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL5
  entrez: '6374'
- word: Danger
  symbol: DANGER
  source: hgnc_alias_symbol
  hgnc_symbol: ITPRIP
  entrez: '85450'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRD
  entrez: '6964'
- word: •CTLA-4
  symbol: CTLA4
  source: hgnc_symbol
  hgnc_symbol: CTLA4
  entrez: '1493'
- word: CD80
  symbol: CD80
  source: hgnc_symbol
  hgnc_symbol: CD80
  entrez: '941'
- word: •IL-6
  symbol: IL6
  source: hgnc_symbol
  hgnc_symbol: IL6
  entrez: '3569'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: HIF1A
  entrez: '3091'
- word: HIF-1a
  symbol: HIF-1alpha
  source: hgnc_alias_symbol
  hgnc_symbol: HIF1A
  entrez: '3091'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFA
  entrez: '5154'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFD
  entrez: '80310'
- word: Chemokine
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL8
  entrez: '3576'
- word: Chemokine
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL10
  entrez: '3627'
- word: Chemokine
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL9
  entrez: '4283'
- word: Chemokine
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: PF4
  entrez: '5196'
- word: •PIGF
  symbol: PIGF
  source: hgnc_symbol
  hgnc_symbol: PIGF
  entrez: '5281'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRG
  entrez: '6965'
- word: ÞFGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF4
  entrez: '2249'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRB
  entrez: '6957'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRA
  entrez: '6955'
- word: CXCL11
  symbol: CXCL11
  source: hgnc_symbol
  hgnc_symbol: CXCL11
  entrez: '6373'
- word: CXCL12
  symbol: CXCL12
  source: hgnc_symbol
  hgnc_symbol: CXCL12
  entrez: '6387'
- word: CXCL16
  symbol: CXCL16
  source: hgnc_symbol
  hgnc_symbol: CXCL16
  entrez: '58191'
- word: TGF-BR1
  symbol: TGFBR1
  source: hgnc_symbol
  hgnc_symbol: TGFBR1
  entrez: '7046'
- word: TLR
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR2
  entrez: '7097'
- word: TLR
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR3
  entrez: '7098'
- word: TLR
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR9
  entrez: '54106'
- word: TLR
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR8
  entrez: '51311'
- word: HGF
  symbol: HGF
  source: hgnc_symbol
  hgnc_symbol: HGF
  entrez: '3082'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: EPAS1
  entrez: '2034'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: ARNT2
  entrez: '9915'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: HIF3A
  entrez: '64344'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: ARNTL
  entrez: '406'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: ARNT
  entrez: '405'
- word: TLR
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR5
  entrez: '7100'
- word: TLR
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR10
  entrez: '81793'
- word: •TN-C
  symbol: TNC
  source: hgnc_symbol
  hgnc_symbol: TNC
  entrez: '3371'
- word: •TNF-a
  symbol: TNF-alpha
  source: hgnc_alias_symbol
  hgnc_symbol: TNF
  entrez: '7124'
- word: TNF-a
  symbol: TNF-alpha
  source: hgnc_alias_symbol
  hgnc_symbol: TNF
  entrez: '7124'
- word: IL-10
  symbol: IL-10
  source: hgnc_alias_symbol
  hgnc_symbol: IL10
  entrez: '3586'
- word: •IL-2
  symbol: IL2
  source: hgnc_symbol
  hgnc_symbol: IL2
  entrez: '3558'
- word: IL-2
  symbol: IL-2
  source: hgnc_alias_symbol
  hgnc_symbol: IL2
  entrez: '3558'
- word: asB1
  symbol: ASB1
  source: hgnc_symbol
  hgnc_symbol: ASB1
  entrez: '51665'
- word: CD28
  symbol: CD28
  source: hgnc_symbol
  hgnc_symbol: CD28
  entrez: '940'
- word: CD8
  symbol: CD8
  source: bioentities_symbol
  hgnc_symbol: CD8A
  entrez: '925'
- word: CD8
  symbol: CD8
  source: bioentities_symbol
  hgnc_symbol: CD8B
  entrez: '926'
- word: CD86
  symbol: CD86
  source: hgnc_symbol
  hgnc_symbol: CD86
  entrez: '942'
- word: Chemokine
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL13
  entrez: '10563'
- word: Chemokine
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL1
  entrez: '2919'
- word: ÞFGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF12
  entrez: '2257'
- word: ÞFGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF11
  entrez: '2256'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFC
  entrez: '56034'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFB
  entrez: '5155'
- word: •PD-L1
  symbol: PD-L1
  source: hgnc_alias_symbol
  hgnc_symbol: CD274
  entrez: '29126'
- word: PD-L1
  symbol: PD-L1
  source: hgnc_alias_symbol
  hgnc_symbol: CD274
  entrez: '29126'
- word: ÞFGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF7
  entrez: '2252'
- word: ÞFGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF6
  entrez: '2251'
- word: ÞFGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF5
  entrez: '2250'
- word: TLR
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR6
  entrez: '10333'
- word: ÞFGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF3
  entrez: '2248'
- word: TGF-B
  symbol: TGFB
  source: bioentities_symbol
  hgnc_symbol: TGFB1
  entrez: '7040'
- word: TGF-B
  symbol: TGFB
  source: bioentities_symbol
  hgnc_symbol: TGFB2
  entrez: '7042'
- word: TGF-B
  symbol: TGFB
  source: bioentities_symbol
  hgnc_symbol: TGFB3
  entrez: '7043'
- word: ÞFGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF1
  entrez: '2246'
- word: ÞFGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF23
  entrez: '8074'
- word: ÞFGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF19
  entrez: '9965'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: TLR
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR7
  entrez: '51284'
- word: IL-6
  symbol: IL-6
  source: hgnc_alias_symbol
  hgnc_symbol: IL6
  entrez: '3569'
- word: TLR
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR1
  entrez: '7096'
- word: TLR
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR4
  entrez: '7099'
- word: •PD-1
  symbol: PD-1
  source: hgnc_alias_symbol
  hgnc_symbol: PDCD1
  entrez: '5133'
- word: PD-1
  symbol: PD-1
  source: hgnc_alias_symbol
  hgnc_symbol: PDCD1
  entrez: '5133'
- word: ÞFGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF13
  entrez: '2258'
- word: ÞFGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF17
  entrez: '8822'
- word: ÞFGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF16
  entrez: '8823'
- word: ÞFGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF10
  entrez: '2255'
- word: ÞFGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF9
  entrez: '2254'
- word: ÞFGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF8
  entrez: '2253'
- word: •OX40
  symbol: OX40
  source: hgnc_alias_symbol
  hgnc_symbol: TNFRSF4
  entrez: '7293'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
- word: ÞFGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF2
  entrez: '2247'
- word: NKG2D
  symbol: NKG2-D
  source: hgnc_alias_symbol
  hgnc_symbol: KLRK1
  entrez: '22914'
- word: ÞFGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF14
  entrez: '2259'
- word: ÞFGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF22
  entrez: '27006'
- word: ÞFGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF18
  entrez: '8817'
- word: VEGF-A
  symbol: VEGF-A
  source: hgnc_alias_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: ÞFGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF21
  entrez: '26291'
- word: ÞFGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF20
  entrez: '26281'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
---
